Zensar Technologies Limited has confirmed that the merger of its US subsidiary Bridgeview Life Sciences LLC into Zensar Technologies Inc. became effective on August 1, 2026. The company disclosed that all requisite filings with relevant local authorities and state agencies were completed on July 30, 2026. This development marks a significant step in the broader restructuring plan approved by the Board of Directors on July 29, 2026, which aims to consolidate two US-based step-down subsidiaries into the material wholly owned subsidiary, Zensar Technologies Inc.

The second part of the restructuring, involving the merger of M3BI LLC with Zensar Technologies Inc., is currently underway. Filings for this transaction are in progress, with no specific effective date disclosed yet. The entire consolidation process is governed by internal group approvals and local regulatory requirements in the United States, rather than Indian shareholder approval, as it involves wholly owned subsidiaries.

The strategic rationale for merging Bridgeview Life Sciences LLC and M3BI LLC into Zensar Technologies Inc. remains focused on driving business synergies and enhancing operational efficiencies. By unifying control over operations across its North American footprint, Zensar Technologies seeks to streamline management structures and reduce administrative overheads. All three entities operate in the digital solutions and technology services sector, serving global organizations.

Financial Overview of Entities Involved

Financial details of the entities involved, based on standalone figures for the year ended March 31, 2026, underscore the scale of the integration. The following table summarises the key financial metrics of the entities participating in the restructuring:

Regulatory Compliance and Shareholder Impact

The transaction does not constitute a related-party transaction under Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as it involves wholly owned subsidiaries within the group structure. Consequently, there will be no change in the shareholding pattern of Zensar Technologies Limited consequent to this merger. No cash consideration or share exchange ratio is applicable since the transaction is internal to the group's US operations.

The proposal was initially considered by the Boards of the respective merging entities and Zensar Technologies Inc., USA. The disclosure regarding the effective date of the Bridgeview merger was made pursuant to Regulation 30(1) of the SEBI Listing Regulations, read with the SEBI Master Circular dated January 30, 2026. The company received intimation of the completion of filings at 03:00 a.m. (IST) on July 31, 2026.

Zensar Technologies published its unaudited consolidated financial results for the quarter ended June 30, 2026, in Financial Express and Loksatta on July 31, 2026, complying with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Pune-based IT services firm reported an 8.9% year-on-year revenue increase to ₹15,083 million ($159.5 million), driven by strong performance in the Banking and Financial Services (BFSI) vertical. Net profit remained stable at ₹1,838 million ($19.4 million), up 1% from ₹1,820 million in Q1FY26, while EBITDA margin contracted to 14.6%, down 150 basis points sequentially due to transition costs from large new deals.

The results were approved by the Board of Directors at its meeting held on July 29, 2026, and reviewed by statutory auditors S R B C & Co LLP pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also disclosed standalone revenue from operations of ₹7,632 million for the quarter, compared to ₹7,418 million in the prior quarter.

Key Financial Metrics

The following table summarises the key financial performance indicators for the quarter:

In constant currency terms, revenue grew by 1.1% sequentially but declined by 2.0% year-on-year, reflecting foreign exchange fluctuations. The company maintained a strong balance sheet with net cash and cash equivalents of $317.5 million, a 0.6% increase year-on-year. Profit after tax stood at 12.2% of revenue, a sequential decrease of 220 basis points.

Segment Performance

Banking and Financial Services (BFSI) emerged as the primary growth engine, contributing 48.8% of total revenue. The vertical registered an 8.3% quarter-on-quarter and 14.7% year-on-year growth in constant currency terms. Conversely, other verticals faced headwinds. Telecommunication, Media and Technology (TMT) revenue declined by 28.0% year-on-year in constant currency, while Healthcare and Life Sciences (HLS) fell by 8.7%. Manufacturing and Consumer Services (MCS) also saw a 3.4% year-on-year decline.

Geographically, the US region accounted for 66.2% of revenue, growing 2.5% sequentially but declining 3.7% year-on-year in constant currency. Europe contributed 21.5% of revenue, with a 3.0% year-on-year growth in constant currency despite a 1.4% sequential decline. Africa's contribution stood at 12.3%, showing minimal change with a 0.8% year-on-year decline.

What the Numbers Show

A notable divergence exists between top-line growth and margin contraction. While revenue grew sequentially, EBITDA dropped by 8.6% to $23.3 million. Management attributed this to a 200-basis point impact from large deal transitions and higher direct costs for travel, visas, and training, suggesting that recent wins — particularly in AI-driven projects — are currently cost-intensive during the mobilization phase. Client concentration remains stable, with the top 20 clients contributing 56.6% of revenue, slightly up from 56.0% in Q4FY26. The number of clients generating over $10 million in revenue increased to 19 from 15 in the previous quarter, indicating deeper engagement with key accounts. Operating expenses as a percentage of revenue improved to 15.1% from 16.5% in Q4FY26, demonstrating some operational leverage despite the margin pressure from direct costs.

Strategic Wins and Outlook

Zensar secured several significant AI-focused wins in Q1FY27, including grants lifecycle modernization for a leading US property insurer and payments optimization for a global energy leader. CEO Manish Tandon highlighted broad-based volume gains despite a challenging macroeconomic environment characterized by prolonged decision cycles. CFO Pulkit Bhandari noted that these large deals strengthen positioning for high-value strategic programs.

The company also reported improved human capital metrics, with total headcount rising to 11,342 from 10,779 in FY26. Voluntary attrition decreased to 9.6% from 9.8% in the previous period, and utilization rates improved to 85.1%. Zensar was recognized as a Leader in Everest Group's Guidewire Services PEAK Matrix Assessment 2026 and ranked #1 in IT Services in Great Place to Work's 'Best Companies to Work For 2026'.

The company has created Zensar Employees Welfare Trust (the 'ESOP Trust') for providing share-based payments under Employee Stock Option Scheme 2025. As at June 30, 2026, ESOP Trust has acquired 781,257 Equity shares from the open market which are treated as Treasury Shares by the Company. No further impact from New Labour Codes was recognised during the quarter ended June 30, 2026.